Smart scans could spare lymphoma patients from extra chemo
NCT ID NCT03758989
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests whether PET scans and blood tests for tumor DNA can help doctors adjust chemotherapy for people with early-stage diffuse large B-cell lymphoma (DLBCL). About 40 participants will receive standard R-CHOP treatment, and their response will be monitored with imaging and blood tests. The goal is to see if these tools can identify who needs less or more treatment, potentially reducing side effects while maintaining effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Rochester
RECRUITINGRochester, New York, 14642, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP)
What this could lead to
If successful, this could lead to more personalized treatment for early-stage DLBCL, reducing unnecessary chemotherapy and side effects.
What could go wrong
This is a small, early-phase study (40 participants) focused on monitoring, not a new treatment. The approach may not improve outcomes or be widely applicable.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.